A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)

Diseases and Conditions Researched


What is the purpose of this trial?

This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of single doses of odanacatib in mature adolescents and young adults who are currently receiving glucocorticoid therapy.

Participation Guidelines

Age: 12 Years - 25 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Merck Sharp & Dohme
Last Updated:
Study HIC#: 1210010939